Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

X-linked agammaglobulinaemia.

E A Goddard1, D W Beatty

  • 1Department of Paediatrics and Child Health, University of Cape Town.

South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
|December 2, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of a single MPV17 nonsense-associated altered splice variant in 24 South African infants with mitochondrial neurohepatopathy.

Clinical genetics·2018
Same author

Endoscopy findings in HIV-infected children from sub-Saharan Africa.

Journal of tropical pediatrics·2009
Same author

HIV infection of undetermined origin during infancy.

Journal of paediatrics and child health·2003
Same author

X-linked agammaglobulinaemia and the underlying genetics in two kindreds.

Journal of paediatrics and child health·2000
Same author

Cryptosporidiosis of the gastrointestinal tract associated with sclerosing cholangitis in the absence of documented immunodeficiency: Cryptosporidium parvum and sclerosing cholangitis in an immunocompetent child.

Journal of pediatric gastroenterology and nutrition·2000
Same author

Are children with clefts underweight for age at the time of primary surgery?

Plastic and reconstructive surgery·1999
Same journal

SAMA Health Summit Abstracts.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same journal

On behalf of the South African Medical Association (SAMA), The Scientific Committee of the SAMA Health Summit, is pleased to pesent this abstract issue, showcasing the posters and oral presentations delivered at the Summit, which was held from 22-24 May 2026.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same journal

Proceedings of the 2<sup>nd</sup> Data Driven Surgery Conference (DDSC 2025).

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same journal

Clinical practice guidelines for the management of fever and neutropenia in South African children and adolescents with cancer.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same journal

The changing fortunes of the District Health System in SA (1994 - 2020): A retrospective review.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
Same journal

Thomas Micheal Guntram Ignaz Rehle (1951 - 2025).

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2026
See all related articles

X-linked agammaglobulinaemia (XLA) is a rare genetic disorder where males lack B cells and immunoglobulins, leading to recurrent infections. Intravenous immunoglobulin therapy is effective, with individualized dosing crucial for optimal patient outcomes.

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • X-linked agammaglobulinaemia (XLA) is a primary immunodeficiency characterized by absent B cells and pan-hypogammaglobulinaemia.
  • It affects only males, leading to recurrent pyogenic infections from infancy.
  • Normal T-cell function is preserved in XLA patients.

Purpose of the Study:

  • To describe the clinical characteristics and management of X-linked agammaglobulinaemia (XLA) in a cohort of patients.
  • To evaluate the efficacy of gammaglobulin replacement therapy in managing XLA.
  • To provide insights into the optimal dosing and administration of intravenous immunoglobulin (IVIG) for XLA.

Main Methods:

  • Retrospective case series analysis of ten patients diagnosed with XLA over 14 years.

Related Experiment Videos

  • Clinical data collection including infection history, lymphoid tissue status, and family history.
  • Assessment of treatment outcomes with intravenous gammaglobulin (IVIG) therapy, including dosage and frequency.

    • Main Results:

    • Half of the patients experienced chronic infections, with two deaths reported.
    • Intravenous gammaglobulin (IVIG) replacement therapy demonstrated superiority over intramuscular administration.
    • A recommended IVIG dose of 200-400 mg/kg/month was noted, emphasizing individualization.

    Conclusions:

    • XLA necessitates lifelong management with immunoglobulin replacement therapy.
    • Intravenous immunoglobulin (IVIG) is the preferred route for gammaglobulin replacement in XLA.
    • Individualized dosing and frequency of IVIG are essential for optimizing treatment efficacy and patient outcomes in XLA.